HLB1 015
Alternative Names: HLB1-015Latest Information Update: 28 Feb 2025
At a glance
- Originator Huonslab
- Class Obesity therapies; Peptides
- Mechanism of Action Glucagon-like peptide 2 receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 07 Jan 2025 Preclinical trials in Obesity in South Korea (Parenteral) (Huonslab pipeline, January 2024)